SoftBank Seeks Over $11 Billion in Junk Bonds for OpenAI Bet
THE SO WHAT
When a conglomerate raises over $11B in junk bonds to double down on one AI platform, AI exposure is becoming a structured asset class, not just equity risk. CFOs with indirect OpenAI dependence should assume more financial engineering around core infra and model access—and model that counterparty and concentration risk explicitly.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureAdaptive, which sells accounting software to construction contractors, raised a $30M Series B led by Tidemark, bringing its total raised to $57M
Vertical SaaS for construction finance is still attracting real capital — $30M into Adaptive is a bet that workflow depth beats generic ERP in messy, project-based industries. If you sell into construction, assume your customers will expect domain-native financial tooling, not horizontal accounting with a few templates.
Startups & VentureAided by AI, young people in China launched 7M+ one-person startups in 2025 to escape a bleak job market, up ~42% from 2024, as they face fierce competition
A 42% jump to 7M+ solo AI businesses in a year is a labor-structure story — AI is turning unemployment into hyper-fragmented micro-entrepreneurship. For operators, this is both a demand pool and a competitor set: expect more niche tools, services, and content from one-person shops, and more pricing pressure at the edges of your product.
Startups & VentureFirmus Seeks to Raise $5 Billion in Landmark Australian IPO
A $5B IPO for a data center operator is another marker that compute and power are now treated as core infrastructure, not just REIT-like yield assets. If you’re building AI-heavy products, assume your landlords — the data center operators — will have more pricing power and strategic leverage over time.
Startups & VentureMithrl, which integrates its proprietary biomedical world model with the R&D systems of pharmaceutical companies, raised a $20M Series A led by Obvious Ventures
Biopharma is starting to pay for AI that plugs directly into existing R&D systems, not just standalone discovery tools. If Mithrl’s “biomedical world model” can sit in the loop with pharma workflows, expect procurement teams to favor vendors that integrate with ELNs, LIMS, and trial stacks out of the box.